Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00964-x
Abstract: Introduction Antiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive… read more here.
Keywords: phase studies; safety; onapristone; extended release ... See more keywords